55.610USD+55.610盤後交易 07/29, 20:00 (美東)
關鍵數據
55.600今開
56.630最高
740.19K成交量
49.91本益比TTM
42.74本益比動
--股利TTM
0.93%換手率
55.610昨收
54.715最低
30.76M成交額
183.96本益比靜
3.30市淨率
0.00%股息率 TTM
6.40%ROA
50.71052週最高
1.08量比
24.14M淨利潤
79.79M總股本
1.1150每股盈餘TTM
1.98Beta
6.93%ROE
22.61052週最低
3.44%振幅
72.32%毛利率
4.44B總市值
-2.74回報/風險
2.78%風險率
操作建議
Veracyte Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名23/385位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為57.83。中期看,股價處於上升通道。近一個月,市場表現較差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。
壓力支撐

由於公司未披露,未能獲取相關數據
Veracyte Inc新聞
即將為您帶來更多新聞,敬請期待。 。 。
收益預測
Ionis Pharmaceuticals Inc
IONS
26
技術指標
財務指標
每股收益

由於公司未披露,未能獲取相關數據
營業總收入

由於公司未披露,未能獲取相關數據
Veracyte Inc簡介
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
公司代碼VCYT
公司Veracyte Inc
CEOStapley (Marc A)
網址https://www.veracyte.com/
公司股東
常見問題
Veracyte Inc(VCYT)的當前股價是多少?
Veracyte Inc(VCYT)的當前股價是 55.65。
Veracyte Inc股票的52週最高點是多少?
Veracyte Inc股票的52週最高點是50.71。
Veracyte Inc股票的52週最低點是多少?
Veracyte Inc股票的52週最低點是22.61。
現在Veracyte Inc(VCYT)的股票是買入、持有還是賣出?
根據分析師評級,Veracyte Inc(VCYT)的總體評級為買入,目標價格為57.83。
Veracyte Inc(VCYT)股票的每股收益(EPS TTM)是多少
Veracyte Inc(VCYT)股票的每股收益(EPS TTM)是0.84。